

# BE CONFIDENT

with accurate, scenario-specific epidemiology data delivering a clear commercial understanding of disease burden and patient populations.




In the era of evidence-based medicine, high-quality and detailed epidemiological data is essential for all strategic activities that require a deep understanding of patient populations.



Forecasting, portfolio prioritisation and asset valuation decisions require increasingly detailed and reliable epidemiology data. However, drawing confident conclusions about the spread and burden of disease is difficult to achieve. It's time consuming to gather all the necessary data; and experts are required to evaluate, standardise and consolidate multiple epidemiological data sources into a single body of evidence.

The market shift to targeted therapies requires granular detail on patient sub-populations and patient flow journeys in order to accurately determine commercial potential and avoid over- or under-forecasting the opportunity. Data therefore needs to be both broad and interrogatable to a highly granular level of detail.





# **HOW WE SUPPORT YOUR SUCCESS**

Curated by epidemiology experts, Evaluate Epi delivers comprehensive, global epidemiological data in granular detail – all in one place.

With easy access to a wealth of disease profiling and epidemiology data that has been expertly collated, curated and correlated, you save time and effort. **Apply epidemiology-based insights to key business activities within minutes, rather than days.** 

Only Evaluate Epi delivers extensive market coverage, deeply granular detail, the ability to link to Evaluate commercial data to help analyse to the extent needed to accurately identify opportunity, model change and generate business-critical insights.

## **EVALUATE EPI IS IDEAL FOR:**



Forecasting



Disease profiling and patient segmentation



Clinical trial planning and design



Lifecycle management



Asset screening and prioritisation



Product valuations



**Product forecasts** 



Market sizing



**Budget** impact analysis



# **WHAT SETS EVALUATE EPI APART?**

## **HIGHLY DETAILED COVERAGE**

Access impartial data for 15 therapeutic areas, more than 230 indications and over 9,500 sub-populations across 27 core markets (up to 49 for some countries), along with longer forecasting horizons, so you have the perspective needed to confidently identify opportunity, model change and understand commercial value.

- Rare diseases (155+)
- · Oncology (40+)
- Expertise in applying disease modelling techniques to more accurately model disease with difficult-to-find data

### **GRANULAR PATIENT LEVEL DATA**

This reflects the complexity of disease segmentation covering over 9,500 patient sub-populations/addressable markets:

- Split by age, gender and country; line of therapy; diagnosed, treatment eligible and treated
- Biomarkers (e.g., PD-L1, BRCA, HER2+/-, BRAF)
- Sub-population analysis of ultra-rare or rare diseases and other niche populations
- Further quantification of rare subpopulations of a disease (e.g., AML within Leukaemia)

## **HIGH QUALITY, ROBUST DATA**



Over 94 sources per disease on average (some with more than 200)



Triple point checked: curated and validated by epidemiology specialists using external and internal sources, proven tools and techniques



Transparent and interrogatable methodologies with all underlying sources available



Data which is trusted by major biopharma, consultancies and investment houses



Proprietary modelling of rare disease and conditions where there are limited data sets readily available



Data regularly updated: once every two years in most cases, with more topical or major areas updated more frequently



# WHAT SETS EVALUATE EPI APART?

### **HOW WE HELP**

- 1. Conduct detailed disease profiling to understand how your patient population will change
- 2. Quantify patient populations against total potential and addressable market for asset valuations, market sizing or budget impact analysis
- 3. Leverage commercial data linkage to integrate commercial and pipeline analysis and build robust product valuations across populations and segments
- 4. Access health economics modelling to forecast changes in target patient populations, drivers and sales impact
- 5. Tailor the patient population to your asset's label

# **BOOK A DEMO**

WWW.EVALUATE.COM/CONTACT



# **HOW CAN WE HELP YOU?**

### WWW.EVALUATE.COM



## **EVALUATEPHARMA**



# **EVALUATEVANTAGE**

#### **EVALUATE HEADQUARTERS**

Evaluate Ltd.
3 More London Riverside
London SE1 2RE
United Kingdom

T +44 (0)20 7377 0800

#### **EVALUATE AMERICAS**

EvaluatePharma USA Inc. 60 State Street, Suite 1910 Boston, MA 02109 USA

T +1 617 573 9450

### **EVALUATE ASIA PACIFIC**

Evaluate Japan KK Holland Hills Mori Tower 2F 5-11-2 Toranomon, Minato-ku Tokyo 105-0001, Japan

T +81-80-1164-4754

## **FIND OUT MORE**

WWW.EVALUATE.COM/PRODUCTS-SERVICES/ EVALUATE-PHARMA/EVALUATE-EPI

